Synergistic interaction of olaparib and cisplatin
In vitro profiling confirms clinically approved combinations
 Esposito et al. (2015) Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors, Nature Medicine, 21:1481-1490.
 Dasgupta et al. (2018) Drugging DNA repair to target T-ALL cells, Leukemia & Lymphoma. 59, 1746–1749.
Fixed-ratio combination experiment of olaparib and cisplatin in MOLT-4 cells. The curves of the mixtures (red, orange, pink) show a shift to the left compared to the single agent curves (green, blue), indicating synergy. This is confirmed by the CI-values that are < 1 (right, above) and the isobologram (left, below).